Awards
| Award From | Category | Type | Award | Year Sort descending | Center(s) | Applications | Description |
|---|---|---|---|---|---|---|---|
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | Development of Large Scale Production, Anti-HIV Microbicide in Soya Beans | 2018 | NCI | HIV microbicides are not currently sold commercially, and many other HIV prevention techniques remain unavailable or unfeasible in developing countries where the disease is most prevalent. The technology transfer effort of developing large scale production methods of CV-N in soy beans helps to… | |
United States Patent and Trademark Office (USPTO) |
Award | Patents for Humanity | Development of a Temperature-Tolerant Rotavirus Vaccine | 2018 | NIAID | Vaccines | Low cost rotavirus vaccine in developing countries, ROTASIIL, a heat stable rotavirus vaccine, was approved by the Drug General Controller of India in 2017. The Government of India subsequently ordered 3.8 million doses of ROTASIIL for its Universal Immunization Program. ROTASIIL is based on a… |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | Protecting Healthcare Workers by Detecting Contamination From Hazardous Antineoplastic Drugs | 2019 | CDC, NIAID | Consumer Products | CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by… |
Federal Laboratory Consortium (FLC) |
Award | Excellence in Technology Transfer | Protecting Healthcare Workers by Detecting Contamination From Hazardous Antineoplastic Drugs | 2019 | CDC, NIAID | Consumer Products | CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by… |
Foundation for the NIH |
Award | Trailblazer Prize for Clinician-Scientists | Foundation for the NIH Awards 2019 Trailblazer Prize For Clinician-Scientists to Dr. James Kochenderfer | 2019 | NCI | Therapeutics | The Foundation for the National Institutes of Health (FNIH) bestowed the 2nd annual Trailblazer Prize for Clinician-Scientists (Trailblazer Prize) to James Kochenderfer, M.D., of the National Cancer Institute (NCI) in October 2019. Dr. Kochenderfer received the Trailblazer Prize and a $10,000… |
Federal Laboratory Consortium (FLC) |
National Award | Innovation Award | Lab to Market Training for Post-doctoral Scientists Across the NIH | 2020 | NCI | In September 2016, to better engage and educate the scientific community, the NCI TTC launched the first federal Technology Transfer Ambassadors Program (TTAP). The program has significantly impacted TT efforts at the NCI and is now being offered across the NIH. TTAP is the first formal TT training… | |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | New, First-in-class Immunotherapy for Treatment of Recurrent, Metastatic Cervical Cancer | 2020 | NCI | Therapeutics | In 2011, NCI and Iovance Biotherapeutics entered into a CRADA for the development of Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL). Technology licenses between NCI and Iovance were established to grant Iovance rights to the NIH’s TIL patent estate. By 2019, Iovance began… |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | CDC’s Assay for Global Surveillance of Drug-resistant HIV-1 Was Commercialized | 2020 | CDC | Diagnostics | Researchers at the Centers for Disease Control and Prevention (CDC) developed a low-cost technology to rapidly detect HIV-1 drug resistance (HIVDR) in plasma and dried blood spot (DBS) samples with 95.8% genotyping sensitivity. CDC’s partners at Life Technologies Corporation (“LifeTech”) have… |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | CDC & NIAID Facilitate the Transfer of a CDC Trap for Control and Surveillance of Mosquitos, a Vital Public Health Tool | 2021 | NIAID, CDC | Consumer Products | The Technology Transfer and Intellectual Property Office (TTIPO) at NIAID, in partnership with the CDC, oversaw licensing and patenting of a low-cost and pesticide-free trap to monitor and control mosquito populations. Mosquitoes can spread deadly viruses — such as dengue, Zika, chikungunya, and… |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | Rapid Sharing of SARS-CoV-2 Prefusion Stabilized Spike Proteins and Plasmids | 2021 | NIAID | Research Materials | Within hours of the public release of the viral genome sequence, scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) and their collaborators engineered a key protein from SARS-CoV-2, the virus that causes COVID-19, to enable its study… |
Federal Laboratory Consortium (FLC) |
National Award | State and Local Economic Development Award | Annual National Cancer Institute and Frederick National Laboratory Technology Showcase | 2021 | NCI | The National Cancer Institute’s (NCI) Technology Transfer Center (TTC) has taken home a State and Local Economic Development award from the 2021 Federal Laboratory Consortium (FLC) awards. The NCI TTC started a yearly event in 2017 with the Frederick National Laboratory (FNL) to highlight… | |
Federal Laboratory Consortium (FLC) |
National Award | State and Local Economic Development Award | SARS-CoV-2 Virus Specimen and Material Sharing | 2021 | NIAID, CDC | Research Materials | The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples… |
Federal Laboratory Consortium (FLC) |
National Award | Impact Award | Enable ACTT Trial to Test Remdesivir as a COVID-19 Treatment | 2021 | NIAID | Therapeutics | The National Institute for Allergy and Infectious Diseases (NIAID) has been recognized by the FLC for their impact on the public through their technology transfer work. On February 21, 2020 NIAID’s Division of Microbiology and Infectious Diseases (DMID) started an Adaptive COVID-19 Treatment Trial… |
Licensing Executives Society (LES) |
Award | Deals of Distinction™ Award | NIAID License to BioNTech Facilitated the Development of an mRNA Vaccine for SARS-CoV-2 (Comirnaty®) | 2021 | NIAID | Vaccines | The LES Deal of Distinction award recognizes major business transactions involving licensing, that exemplify best practices and creativity to achieve strategic product development objectives, with a significant impact on advancing innovation in the industry sectors that comprise LES which includes… |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | Antibody Focused Collaboration with AbCellera | 2022 | NIAID | Therapeutics | Originally established to study influenza, a partnership between NIAID and biotechnology company AbCellera quickly pivoted to become a major player in the development of antibodybased COVID-19 therapies. One of those therapies, bamlanivimab, has been authorized to treat mild to moderate COVID-19… |
Federal Laboratory Consortium (FLC) |
National Award | Impact Award | NIAID Won 2022 FLC Impact Award for Industry Partnerships That Facilitated NIAID Trials to Support Authorization of COVID-19 Vaccine Candidates | 2022 | NIAID | In response to the COVID-19 outbreak, researchers and technology transfer professionals at NIAID accelerated collaborations with COVID-19 vaccine developers that enabled the rapid study, emergency authorization and public use of urgently needed vaccines. The results of these efforts became… | |
United States Patent and Trademark Office (USPTO) |
Award | Patents for Humanity | NIAID Won Patents for Humanity: COVID-19 Category Award for Stabilized Coronavirus Spike Proteins | 2022 | NIAID | Vaccines | The United States Patent and Trademark Office (USPTO) recognized NIAID TTIPO’s public health-centered patent management efforts with the Patents for Humanity: COVID-19 category award with the USPTO announcing the award on December 15, 2022. NIAID, Scripps Research Institute, and Dartmouth College… |
Licensing Executives Society (LES) |
National Award | Deals of Distinction™ Award | COVID-19 Technologies Licensed Globally Through WHO Program Win LES Deals of Distinction Award | 2022 | NIAID | Diagnostics, Therapeutics, Vaccines | NIAID TTIPO’s extraordinary efforts in “COVID-19 Technologies Licensed Globally Through WHO Program” was recognized by the Licensing Executives Society (U.S.A. & Canada) in 2022 with a Deals of Distinction Award in the Industry-University-Government Interface Sector. This award acknowledged the… |
Licensing Executives Society (LES) |
Award | Deals of Distinction™ Award | NIH Wins Licensing Executive Society Deals of Distinction Award for WHO C-TAP Partnership | 2022 | Diagnostics, Therapeutics, Vaccines | The NIH Technology Transfer Program has won the Licensing Executive Society’s Deals of Distinction award for 2022. The Deals of Distinction Award is given to an outstanding licensing deal from the past year. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer, recently attended… | |
Licensing Executives Society (LES) |
Award | Deals of Distinction™ Award | One-Time Gene Therapy for hemophilia B | 2023 | NHLBI | Therapeutics | The Licensing Executives Society (LES) has recognized with its “Deals of Distinction” Award licenses granted by the NIH intramural research program to uniCure N.V. based in Amsterdam along with its global partner CSL Behring. As a result of these licenses on November 22, 2022, the U.S. Food… |
U.S. Department of Health and Human Services (HHS) |
Award | Enterprise Technology Transfer Implementation Team Receives Honorable Mention from HHS Data Excellence Awards | 2023 | OD | Software / Apps | The Enterprise Technology Transfer system received an Honorable Mention from the HHS Data Excellence Award in the Distinguished Federal Data Modernization category. Creating ETT as a centralized source for NIH technology transfer data has advanced federal data initiatives by enhancing users’… | |
|
Award | Dr. Ken Jacobson Wins E.B. Hershberg Award | 2023 | NIDDK | Therapeutics | The American Chemical Society (ACS) has awarded Kenneth Jacobson the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. Jacobson is a Senior Investigator at the National Institute for Diabetes and Digestive and Kidney Diseases.Jacobson was selected for this award for… | |
|
Award | Digital Health Transformation Award | NIH Wins GOVTECH CONNECT’s Digital Health Transformation Award | 2024 | OD | Software / Apps | The National Institutes of Health (NIH) Enterprise Technology Transfer (ETT) system has been selected as a GOVTECH CONNECTS’s Digital Health Transformation Award Recipient.The Digital Health Transformation Award recognizes Federal and Military Health IT programs that are harnessing the power of… |
Federal Laboratory Consortium (FLC) |
National Award | Excellence in Technology Transfer | Changing Lives in PASLI/APDS Patients, Disease Discovery and Treatment. | 2024 | NIAID | Therapeutics | THE PROBLEM: APDS (activated PI3 kinase delta syndrome) — also known as PASLI (p110 delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) disease — is a rare disorder that severely impairs the immune system’s ability to fight bacterial and viral infections,… |
Federal Laboratory Consortium (FLC) |
National Award | Impact Award | FDA-Approved RSV Vaccine Based on NIAID’s F Protein Technology | 2024 | NIAID | Vaccines | THE PROBLEM: Respiratory syncytial virus (RSV) is a common virus that typically causes mild, cold-like symptoms — but it can be deadly to older adults, young children and people with chronic heart or lung disease or weakened immune systems. Each year in the U.S., 60,000 to 160,000 adults 65 years… |